{"entity":{"id":"nct05617755","kind":"trial","name":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer","aka":[],"tldr":"A phase 1 trial of AB-1015 run by Arsenal Biosciences, Inc., terminated.","summary":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer is a phase 1 interventional study registered as NCT05617755 by Arsenal Biosciences, Inc., with 19 participants enrolled, started 2022-11-29. Conditions recorded: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm and Recurrence. Interventions recorded: AB-1015.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05617755","url":"https://clinicaltrials.gov/study/NCT05617755"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ab-1015"],"companies":["arsenal-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05617755","phase":"1","setting":"An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer","sponsor":"Arsenal Biosciences, Inc.","enrolled":19,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05617755/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"ab-1015","kind":"drug","name":"AB-1015","route":"/drugs/ab-1015/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"}]}}